Checkpoint inhibitors that block PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, durvalumab, and avelumab) prevent T cell downregulation initiated by PD-1 binding PD-L1 expressed on tumor cells and immune cells (3). This evidence concerns the gene CD274 and neoplasm.